This segment focuses on the research and development of novel immunomodulatory therapies, primarily centered around the lead product candidate, tegoprubart (AT-1501). The core technology involves targeting the CD40 Ligand, a key molecule in T-cell activation, to modulate the immune response in various disease states. Research activities include preclinical studies, Phase 1 and Phase 2 clinical trials across multiple therapeutic areas. The segment aims to address unmet needs in autoimmune diseases, transplant rejection, and neurodegenerative conditions like ALS. By selectively modulating the immune system, the goal is to improve patient outcomes and quality of life while minimizing broad immunosuppression-related side effects. Future opportunities include expanding the application of tegoprubart to other immune-mediated diseases and exploring combination therapies to enhance efficacy.

This segment is dedicated to developing therapies aimed at preventing organ and islet cell transplant rejection. The primary focus is on the BESTOW trial, a Phase 2 clinical trial evaluating tegoprubart in kidney transplantation. The research involves assessing the efficacy and safety of tegoprubart in preventing acute rejection episodes and improving long-term graft survival. The segment addresses the critical need for more effective and targeted immunosuppression strategies in transplant recipients. By selectively modulating the CD40L pathway, tegoprubart aims to minimize the need for conventional immunosuppressants and their associated side effects. Future opportunities include expanding the application of tegoprubart to other types of transplants, such as heart and lung transplants, and exploring novel combination therapies to further enhance graft acceptance and long-term outcomes.

This segment is focused on the development of therapies for neurodegenerative diseases, with a primary emphasis on Amyotrophic Lateral Sclerosis (ALS). The lead product candidate, tegoprubart (AT-1501), is currently in Phase 2a clinical trials for the treatment of ALS. The research involves investigating the potential of tegoprubart to slow disease progression and improve patient outcomes by modulating the immune response in the central nervous system. The segment addresses the significant unmet need for effective treatments for ALS, a devastating and rapidly progressive neurodegenerative disorder. By targeting the CD40L pathway, tegoprubart aims to reduce neuroinflammation and protect motor neurons from further damage. Future opportunities include exploring the application of tegoprubart to other neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and investigating novel biomarkers to identify patients who are most likely to benefit from treatment.